Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | EVP, Global Commercial Ops. | May 03, 2018 | May 07, 2018 |
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | SVP ComOps Pres USJap Int | May 13, 2011 | May 17, 2011 |
| BeOne Medicines Ltd.ONC · Entity 2168 | Director | June 11, 2026 | June 15, 2026 |
| MANNKIND CORPMNKD · Entity 4792 | Director | May 20, 2026 | May 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 03, 2018 · Filed May 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 215,147 |
Reported balance
After 2018-05-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-05-03 · Tax withholding · Disposed 883 · Balance 215,147 F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,563 RSUs which vest in one installment on 1/30/2019; 3,428 RSUs which vest in installments of 1,688 on 5/3/2019 and 1,740 on 5/3/2020; and 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2: These shares include 449 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,563 RSUs which vest in one installment on 1/30/2019; 3,428 RSUs which vest in installments of 1,688 on 5/3/2019 and 1,740 on 5/3/2020; and 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2: These shares include 449 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
BRISTOL MYERS SQUIBB CO
Report date May 13, 2011 · Filed May 17, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 203,170 |
Ending reported balance
After 2011-05-13 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2011-05-13 · Exercise / conversion · Acquired 381,750 · Balance 544,178 Row 2 · 2011-05-13 · Sale · Disposed 13,372 · Balance 530,806 F1: This transaction was executed in multiple trades from $28.7500 to $28.8550. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2011-05-13 · Tax withholding · Disposed 47,869 · Balance 482,937 F2: Shares withheld for payment of taxes and fees upon exercise of stock options. F1: This transaction was executed in multiple trades from $28.7500 to $28.8550. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2011-05-13 · Tax withholding · Disposed 279,767 · Balance 203,170 F3: Shares withheld for payment of exercise price upon exercise of stock options. F1: This transaction was executed in multiple trades from $28.7500 to $28.8550. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Executive Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.51 · Expires 2019-03-02 | Direct | 158,634 |
Reported balance
After 2011-05-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2011-05-13 · Exercise / conversion · Disposed 110,000 · Balance 158,634 F5: Twenty-five percent of the stock option award vests on each of the first, second, third and fourth anniversaries of the grant date. |
| Executive Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.14 · Expires 2018-03-03 | Direct | 46,495 |
Reported balance
After 2011-05-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2011-05-13 · Exercise / conversion · Disposed 125,000 · Balance 46,495 F5: Twenty-five percent of the stock option award vests on each of the first, second, third and fourth anniversaries of the grant date. |
| Executive Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.73 · Expires 2016-03-06 | Direct | 0 |
Reported balance
After 2011-05-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2011-05-13 · Exercise / conversion · Disposed 78,750 · Balance 0 F6: Currently exercisable. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.14 · Expires 2013-03-03 | Direct | 0 |
Reported balance
After 2011-05-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2011-05-13 · Exercise / conversion · Disposed 68,000 · Balance 0 F6: Currently exercisable. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy BMY Savings & Investment Program | 1,573.97 |
Reported balance
Holding disclosure · report date 2011-05-13 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,573.97 F4: Based on a plan statement as of the end of the most recent fiscal quarter. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy Spouse | 3,675 |
Reported balance
Holding disclosure · report date 2011-05-13 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 3,675 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades from $28.7500 to $28.8550. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Shares withheld for payment of taxes and fees upon exercise of stock options.
F3: Shares withheld for payment of exercise price upon exercise of stock options.
F4: Based on a plan statement as of the end of the most recent fiscal quarter.
F5: Twenty-five percent of the stock option award vests on each of the first, second, third and fourth anniversaries of the grant date.
F6: Currently exercisable.
BeOne Medicines Ltd.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 83,720 |
Reported balance
After 2026-06-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 18,980 · Balance 83,720 F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.
MANNKIND CORP
Report date May 20, 2026 · Filed May 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 82,781 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 82,781 · Balance 82,781 F1: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 16,556 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 16,556 · Balance 16,556 F1: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F2: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.
F3: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 21:50 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantOrdinary Shares | 18,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001277244-26-000001 · wk-form4_1781560257.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,720 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy. Read SEC document |
| May 20, 2026 Filed May 23, 2026 00:51 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 16,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-237431 · ownership.xml · derivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,556 Underlying: Common Stock, $0.01 Par Value · 16,556 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F3 · derivative.expiration_date: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 20, 2026 Filed May 23, 2026 00:51 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 82,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-237431 · ownership.xml · derivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,781 Underlying: Common Stock, $0.01 Par Value · 82,781 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 35,000 | $3.27 | $114,450.00 |
DisclosureSEC source: 0001193125-26-089612 · ownership.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,153 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan. The purchase was approved by the Company's Board of Directors on March 1, 2026. Read SEC document |
| May 21, 2025 Filed May 22, 2025 23:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 22,750 | $0.00 Strike: $18.19 | $0.00 |
DisclosureSEC source: 0001651308-25-000085 · wk-form4_1747957297.xml · derivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,750 Underlying: Ordinary Shares · 22,750 shares Expires 2035-05-20 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 21, 2025 Filed May 22, 2025 23:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 10,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000085 · wk-form4_1747957297.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,740 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 14, 2025 Filed May 16, 2025 22:10 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 10,571 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073790 · ownership.xml · derivative · entry 3 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,571 Underlying: Common Stock, $0.01 Par Value · 10,571 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F4 · derivative.exercise_date: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F4 · derivative.expiration_date: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 14, 2025 Filed May 16, 2025 22:10 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 52,854 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073790 · ownership.xml · derivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,854 Underlying: Common Stock, $0.01 Par Value · 52,854 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · kind: Restricted stock unit vested on May 14, 2025, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F3 · derivative.exercise_date: Restricted stock unit vested on May 14, 2025, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F3 · derivative.expiration_date: Restricted stock unit vested on May 14, 2025, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 14, 2025 Filed May 16, 2025 22:10 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 25,000 | $4.56 | $114,000.00 |
DisclosureSEC source: 0000950170-25-073790 · ownership.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,153 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on May 14, 2025. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:00 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 34,151 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001651308-24-000063 · wk-form4_1717794032.xml · derivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,151 Underlying: Ordinary Shares · 34,151 shares Expires 2034-06-04 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:00 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 16,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-24-000063 · wk-form4_1717794032.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,755 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:29 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 35,047 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062082 · ownership.xml · derivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,047 Underlying: Common Stock, $.01 Par Value · 35,047 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| February 04, 2024 Filed Feb 5, 2024 11:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 40,000 | $3.27 | $130,800.00 |
DisclosureSEC source: 0001209191-24-002741 · doc4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,153 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on February 4, 2024. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 26,975 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001651308-23-000096 · wf-form4_168730193754018.xml · derivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,975 Underlying: Ordinary Shares · 26,975 shares Expires 2033-06-14 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 12,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-23-000096 · wf-form4_168730193754018.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,414 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 47,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032722 · doc4.xml · derivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,393 Underlying: Common Stock · 47,393 shares Expires 2033-05-25 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Restricted stock unit vested on May 25, 2023, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 34,645 | $0.00 Strike: $11.98 | $0.00 |
DisclosureSEC source: 0001651308-22-000108 · wf-form4_165610670088035.xml · derivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,645 Underlying: Ordinary Shares · 34,645 shares Expires 2032-06-21 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 16,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-22-000108 · wf-form4_165610670088035.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,492 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share unites were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 45,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028667 · doc4.xml · derivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,045 Underlying: Common Stock · 45,045 shares Expires 2032-05-10 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock,$.01 par value | 40,000 | $2.71 | $108,400.00 |
DisclosureSEC source: 0001209191-22-014097 · doc4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,394 Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 17,498 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001651308-21-000122 · wf-form4_162430788386168.xml · derivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,498 Underlying: Ordinary Shares · 17,498 shares Expires 2031-06-15 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000122 · wf-form4_162430788386168.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| May 20, 2021 Filed May 21, 2021 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 11,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034719 · doc4.xml · derivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,338 Underlying: Common Stock · 11,338 shares Expires 2031-05-20 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: Annual Retainer: Award granted in lieu of annual cash retainer payment. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 20, 2021 Filed May 21, 2021 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 33,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034719 · doc4.xml · derivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,860 Underlying: Common Stock · 33,860 shares Expires 2031-05-20 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 45,383 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000081 · wf-form4_159259818823203.xml · derivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,383 Underlying: Ordinary Shares · 45,383 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| May 21, 2020 Filed May 27, 2020 00:19 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 38,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032196 · doc4.xml · derivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,760 Underlying: Common Stock · 38,760 shares Expires 2030-05-21 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: Annual Retainer: Award granted in lieu of annual cash retainer payment. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 21, 2020 Filed May 27, 2020 00:19 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 88,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032196 · doc4.xml · derivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,235 Underlying: Common Stock · 88,235 shares Expires 2030-05-21 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 01:24 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 30,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016410 · doc4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,201 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Restricted stock unit shall vest immediately, but the shares shall not be delivered until the director leaves the Board. Read SEC document |
| March 03, 2020 Filed Mar 7, 2020 01:29 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 21,970 | $0.00 Strike: $12.22 | $0.00 |
DisclosureSEC source: 0001651308-20-000021 · wf-form4_158354457657923.xml · derivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,970 Underlying: Ordinary Shares · 21,970 shares Expires 2030-03-02 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 03, 2018 Filed May 7, 2018 23:01 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 883 | $169.43 | $149,606.69 |
DisclosureSEC source: 0001127602-18-016536 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,147 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,563 RSUs which vest in one installment on 1/30/2019; 3,428 RSUs which vest in installments of 1,688 on 5/3/2019 and 1,740 on 5/3/2020; and 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 449 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2018 Filed May 1, 2018 23:10 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 34,702 | $0.00 Strike: $177.46 | $0.00 |
DisclosureSEC source: 0001127602-18-015839 · form4.xml · derivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,702 Underlying: Common Stock · 34,702 shares Expires 2028-04-27 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively. Read SEC document |
| April 27, 2018 Filed May 1, 2018 23:10 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 4,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-015839 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,030 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,563 RSUs which vest in one installment on 1/30/2019; 5,116 RSUs which vest in two equal installments of 1,688 on 5/3/2018 and 5/3/2019 and one installment of 1,740 on 5/3/2020; and 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 540 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 23:42 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 8,807 | $176.08 | $1,550,736.56 |
DisclosureSEC source: 0001127602-18-012858 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,522 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,563 RSUs which vest in one installment on 1/30/2019; 5,116 RSUs which vest in two equal installments of 1,688 on 5/3/2018 and 5/3/2019 and one installment of 1,740 on 5/3/2020; and 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 540 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:27 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 17,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011021 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,121 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,563 RSUs which vest in one installment on 1/30/2019; 5,116 RSUs which vest in two equal installments of 1,688 on 5/3/2018 and 5/3/2019 and one installment of 1,740 on 5/3/2020; and 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 456 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 01:38 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 651 | $191.27 | $124,516.77 |
DisclosureSEC source: 0001127602-18-003452 · form4.xml · nonDerivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,483 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,563 RSUs which vest in one installment on 1/30/2019; 5,116 RSUs which vest in two equal installments of 1,688 on 5/3/2018 and 5/3/2019 and one installment of 1,740 on 5/3/2020; and 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 456 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2018 Filed Feb 2, 2018 01:38 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 575 | $198.00 | $113,850.00 |
DisclosureSEC source: 0001127602-18-003452 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,134 Read SEC document |
| May 01, 2017 Filed May 4, 2017 00:50 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 43,572 | $0.00 Strike: $162.60 | $0.00 |
DisclosureSEC source: 0001127602-17-016752 · form4.xml · derivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,572 Underlying: Common Stock · 43,572 shares Expires 2027-05-01 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively. Read SEC document |
| May 01, 2017 Filed May 4, 2017 00:50 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 4,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016752 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,402 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,715 RSUs which vest on 1/31/2018; 3,080 RSUs which vest in two installments of 1,517 and 1,563 on 1/30/2018 and 1/30/2019, respectively; 5,116 RSUs which vest in two equal installments of 1,688 on 5/3/2018 and 5/3/2019 and one installment of 1,740 on 5/3/2020; and 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 426 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 24, 2017 Filed Mar 28, 2017 22:55 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 12,128 | $166.04 | $2,013,733.12 |
DisclosureSEC source: 0001127602-17-013094 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,482 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,715 RSUs which vest on 1/31/2018; 3,080 RSUs which vest in two installments of 1,517 and 1,563 on 1/30/2018 and 1/30/2019, respectively; and 5,116 RSUs which vest in two equal installments of 1,688 on 5/3/2018 and 5/3/2019 and one installment of 1,740 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 426 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 22:08 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 23,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-011091 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,397 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,715 RSUs which vest on 1/31/2018; 3,080 RSUs which vest in two installments of 1,517 and 1,563 on 1/30/2018 and 1/30/2019, respectively; and 5,116 RSUs which vest in two equal installments of 1,688 on 5/3/2018 and 5/3/2019 and one installment of 1,740 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 362 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 31, 2017 Filed Feb 3, 2017 00:03 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 668 | $154.43 | $103,159.24 |
DisclosureSEC source: 0001127602-17-003740 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,305 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,715 RSUs which vest on 1/31/2018; 3,080 RSUs which vest in two installments of 1,517 and 1,563 on 1/30/2018 and 1/30/2019, respectively; and 5,116 RSUs which vest in two equal installments of 1,688 on 5/3/2018 and 5/3/2019 and one installment of 1,740 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 362 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 598 | $157.16 | $93,981.68 |
DisclosureSEC source: 0001127602-17-003201 · form4.xml · nonDerivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,973 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,380 RSUs which vest in two installments of 1,665 and 1,715 on 1/31/2017 and 1/31/2018, respectively; 3,080 RSUs which vest in two installments of 1,517 and 1,563 on 1/30/2018 and 1/30/2019, respectively; and 5,116 RSUs which vest in two equal installments of 1,688 on 5/3/2018 and 5/3/2019 and one installment of 1,740 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 472 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 28, 2017 Filed Feb 1, 2017 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,053 | $157.16 | $165,489.48 |
DisclosureSEC source: 0001127602-17-003201 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,571 Read SEC document |
| May 03, 2016 Filed May 6, 2016 00:30 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 43,557 | $0.00 Strike: $156.35 | $0.00 |
DisclosureSEC source: 0001127602-16-051291 · form4.xml · derivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,557 Underlying: Common Stock · 43,557 shares Expires 2026-05-03 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. Read SEC document |
| May 03, 2016 Filed May 6, 2016 00:30 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 5,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-051291 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,312 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 2,543 RSUs which vest on 1/28/2017; 3,380 RSUs which vest in two installments of 1,665 and 1,715 on 1/31/2017 and 1/31/2018, respectively; 4,597 RSUs which vest in two equal installments of 1,517 on 1/30/2017 and 1/30/2018 and one installment of 1,563 on 1/30/2019; and 5,116 RSUs which vest in two equal installments of 1,688 on 5/3/2018 and 5/3/2019 and one installment of 1,740 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 450 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2016 Filed Apr 29, 2016 23:45 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,659 | $162.85 | $270,168.15 |
DisclosureSEC source: 0001127602-16-050337 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,196 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,543 RSUs which vest on 1/28/2017; 3,380 RSUs which vest in two installments of 1,665 and 1,715 on 1/31/2017 and 1/31/2018, respectively; and 4,597 RSUs which vest in two equal installments of 1,517 on 1/30/2017 and 1/30/2018 and one installment of 1,563 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 450 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 25, 2016 Filed Mar 29, 2016 21:13 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 23,785 | $149.24 | $3,549,673.40 |
DisclosureSEC source: 0001127602-16-047732 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,855 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,943 RSUs which vest on 4/27/2016; 2,543 RSUs which vest on 1/28/2017; 3,380 RSUs which vest in two installments of 1,665 and 1,715 on 1/31/2017 and 1/31/2018, respectively; and 4,597 RSUs which vest in two equal installments of 1,517 on 1/30/2017 and 1/30/2018 and one installment of 1,563 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 685 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 02, 2016 Filed Mar 4, 2016 23:13 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 45,268 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-045128 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,230 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,943 RSUs which vest on 4/27/2016; 2,543 RSUs which vest on 1/28/2017; 3,380 RSUs which vest in two installments of 1,665 and 1,715 on 1/31/2017 and 1/31/2018, respectively; and 4,597 RSUs which vest in two equal installments of 1,517 on 1/30/2017 and 1/30/2018 and one installment of 1,563 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 588 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 31, 2016 Filed Feb 2, 2016 01:30 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 651 | $152.73 | $99,427.23 |
DisclosureSEC source: 0001127602-16-038850 · form4.xml · nonDerivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,962 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,943 RSUs which vest on 4/27/2016; 2,543 RSUs which vest on 1/28/2017; 3,380 RSUs which vest in two installments of 1,665 and 1,715 on 1/31/2017 and 1/31/2018, respectively; and 4,597 RSUs which vest in two equal installments of 1,517 on 1/30/2017 and 1/30/2018 and one installment of 1,563 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 588 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 28, 2016 Filed Feb 2, 2016 01:30 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 995 | $150.47 | $149,717.65 |
DisclosureSEC source: 0001127602-16-038850 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,339 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.